- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01515592
Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers
January 24, 2017 updated by: Novo Nordisk A/S
A Randomised, Double-blind Within Dose Group, Single Centre, Placebo-controlled, Dose Escalation, Multiple s.c. Dose Study to Assess the Safety and Tolerability of Liraglutide 20 ug/kg and 25 ug/kg in Healthy Japanese Male Subjects
This trial is conducted in Japan.
The aim of this trial is to assess the safety and tolerability of 20 µg/kg and 25 µg/kg liraglutide in healthy Japanese male subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan, 1000005
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy Japanese subjects
- BMI (Body Mass Index) between 18.0-27.0 kg/m^2 inclusive
Exclusion Criteria:
- Any clinical laboratory values deviated from the reference range at the laboratory (except for cases within physiological change) or any abnormal ECG (electrocardiogram) findings at the screening
- Presence of diabetes, cancer or any clinically significant cardiac, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal, haematological, neurological, or psychiatric diseases or disorders
- Hepatitis B surface antigen, Hepatitis C antibodies or HIV (human immunodeficiency virus) antibodies positive
- History of diabetes, cancer or any clinically significant cardiac, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal, haematological, neurological, or psychiatric diseases or disorders
- History of significant allergy or hypersensitivity
- Known or suspected allergy to trial product or related products
- History of drug or alcohol abuse
- The subjects who smoke more than 15 cigarettes, or the equivalent, per day and is unwilling to refrain from smoking whenever required for the trial procedure
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 25 mcg/kg
|
One daily subcutaneous dose for 5 weeks.
Dose is weekly incremented with 5 mcg/kg
One daily subcutaneous dose for 5 weeks.
5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
One daily subcutaneous dose for 5 weeks.
5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
|
Experimental: 15 mcg/kg
|
One daily subcutaneous dose for 5 weeks.
Dose is weekly incremented with 5 mcg/kg
One daily subcutaneous dose for 5 weeks.
5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
One daily subcutaneous dose for 5 weeks.
5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
|
Experimental: 20 mcg/kg
|
One daily subcutaneous dose for 5 weeks.
Dose is weekly incremented with 5 mcg/kg
One daily subcutaneous dose for 5 weeks.
5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
One daily subcutaneous dose for 5 weeks.
5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Adverse events
|
Body weight
|
Antibody against liraglutide
|
Secondary Outcome Measures
Outcome Measure |
---|
Cmax, maximum concentration
|
tmax, time to reach Cmax
|
Terminal elimination rate constant
|
Area under the plasma liraglutide concentration curve
|
t½, terminal elimination half-life
|
24-hour profiles of plasma glucose
|
24-hour profiles of serum insulin
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2006
Primary Completion (Actual)
April 1, 2006
Study Completion (Actual)
April 1, 2006
Study Registration Dates
First Submitted
January 18, 2012
First Submitted That Met QC Criteria
January 18, 2012
First Posted (Estimate)
January 24, 2012
Study Record Updates
Last Update Posted (Estimate)
January 25, 2017
Last Update Submitted That Met QC Criteria
January 24, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN2211-1694
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on liraglutide
-
Woman'sNovo Nordisk A/SCompletedPolycystic Ovary Syndrome | Pre Diabetes | Obesity AndroidUnited States
-
Novo Nordisk A/SCompleted
-
The Affiliated Hospital of Qingdao UniversityCompletedTherapeutic EquivalencyChina
-
Sunshine Lake Pharma Co., Ltd.Completed
-
Merck Sharp & Dohme LLCCompleted
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark
-
Parker Research InstituteCompletedOsteoarthritis, KneeDenmark
-
Henrik GudbergsenNovo Nordisk A/S; Cambridge Weight Plan LimitedCompleted
-
Henrik GudbergsenCompletedUltrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance (US-LOSEIT-II)Obesity | OsteoarthritisDenmark
-
Henrik GudbergsenCompletedObesity | OsteoarthritisDenmark